NIJBAS
Publications 2024

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJBAS/2024/5.3.283311

The Role of Tumor-Associated Macrophages in Cancer Immunoevasion and Therapy Resistance

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Tumor-associated macrophages (TAMs) are crucial components of the tumor microenvironment, playing significant roles in cancer progression, immune evasion, and therapy resistance. Originating from circulating monocytes, TAMs can polarize into M1 and M2 phenotypes, with M2-like TAMs predominating in many cancers. This M2 polarization fosters an immunosuppressive environment that promotes tumor growth, metastasis, and resistance to therapies, including chemotherapy and immune checkpoint inhibitors. TAMs secrete various cytokines, chemokines, and growth factors that enhance tumor cell survival, promote angiogenesis, and recruit additional immunosuppressive cells such as regulatory T cells. They also express immune checkpoint molecules, further inhibiting effective anti-tumor immune responses. Given their dual role in supporting tumor survival and mediating immune evasion, TAMs represent an attractive target for therapeutic intervention. Current strategies to target TAMs include depletion, reprogramming, and combination therapies aimed at enhancing anti-tumor immunity. This review explores the complex biology of TAMs, their mechanisms of action in promoting cancer immunoevasion and therapy resistance, and the therapeutic strategies being developed to exploit their unique characteristics. By providing insights into the multifaceted roles of TAMs, this review aims to highlight potential avenues for improving cancer treatment outcomes and addressing the challenges posed by tumor-induced immune suppression.

Keywords: Tumor-Associated Macrophages (TAMs), Immune Evasion, Therapy Resistance, Macrophage Polarization, Immunotherapy

INTRODUCTION

Tumor-associated macrophages (TAMs) have garnered significant attention in cancer research due to their integral role in the tumor microenvironment, where they contribute to tumor progression, immune evasion, and therapy resistance. Originating from monocytes, these macrophages infiltrate tumors and adapt to their surroundings, exhibiting remarkable plasticity that allows them to adopt distinct functional phenotypes [1]. The polarization of macrophages, influenced by various cytokines and environmental cues, determines their roles within the tumor microenvironment and significantly impacts the overall behavior of tumors [2]. In a healthy context, macrophages are pivotal for maintaining tissue homeostasis and orchestrating immune responses. They can adopt pro-inflammatory (M1) or anti-inflammatory (M2) phenotypes, with M1 macrophages typically promoting anti-tumor immunity through the secretion of pro-inflammatory cytokines and enhanced antigen presentation [3]. However, in many cancers, the balance shifts toward a predominance of M2-like TAMs, characterized by immunosuppressive functions and a tendency to support tumor growth and metastasis [4]. This polarization is driven by factors such as interleukin-4 (IL-4), interleukin-13 (IL-13), and transforming growth factor-beta (TGF-β), which foster an environment conducive to tumor progression. TAMs are not merely passive bystanders in the tumor microenvironment; they actively modulate the immune landscape by secreting a plethora of cytokines, chemokines, and growth factors. This secretory profile enhances tumor cell survival, promotes angiogenesis, and facilitates the recruitment of other immunosuppressive cells, such as regulatory T cells (Tregs) [5]. Consequently, the presence of TAMs is associated with poor prognosis in various malignancies, as they play a crucial role in enabling tumors to evade immune surveillance and resist therapeutic interventions [6]. The ability of TAMs to create an immunosuppressive environment is particularly concerning in the context of cancer

ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

immunotherapy. Immune checkpoint inhibitors have revolutionized cancer treatment, yet their efficacy is often limited by the presence of TAMs, which maintain an immunosuppressive milieu through the expression of immune checkpoint molecules like programmed death-ligand 1 (PD-L1) [7]. Additionally, TAMs have been implicated in the development of resistance to conventional therapies, including chemotherapy and targeted therapies [8]. By promoting survival pathways in tumor cells and facilitating DNA repair, TAMs undermine the effectiveness of these treatments and contribute to tumor recurrence. Given their dual role in supporting tumor growth and promoting immune evasion, TAMs represent a compelling target for therapeutic intervention. Strategies aimed at depleting or reprogramming TAMs are currently under investigation, with the hope of enhancing the efficacy of existing cancer therapies. As the understanding of TAM biology deepens, novel approaches to manipulate their function may hold promise for improving patient outcomes and combating therapy resistance. This review will delve into the multifaceted roles of TAMs in cancer immunoevasion and therapy resistance, exploring their origins, polarization, mechanisms of action, and the potential for therapeutic targeting. By shedding light on the complex interplay between TAMs and tumor cells, we aim to contribute to the ongoing efforts to develop effective strategies for combating cancer and improving the effectiveness of current treatment modalities.

Origins and Polarization of Tumor-Associated Macrophages

TAMs are derived primarily from circulating monocytes that are recruited to the tumor site in response to chemokines and other signaling molecules secreted by tumor cells and the surrounding microenvironment [1]. Upon entering the tumor, monocytes can differentiate into macrophages and polarize into distinct phenotypes depending on the local cytokine milieu [9].

Macrophage Polarization

Macrophages can be broadly categorized into two main phenotypes: M1 and M2.

a) M1 Macrophages: These are classically activated macrophages that are typically induced by interferon-gamma (IFN-γ) and lipopolysaccharides (LPS). M1 macrophages are characterized by their pro-inflammatory functions, including the production of cytokines such as TNF-α, IL-1β, and IL-6, as well as their ability to present antigens and produce reactive oxygen and nitrogen species. They are generally associated with anti-tumor activity [10].
b) M2 Macrophages: In contrast, M2 macrophages are alternatively activated and are induced by cytokines such as IL-4 and IL-13. They are associated with tissue repair, immunoregulation, and the promotion of angiogenesis [11]. M2 macrophages secrete anti-inflammatory cytokines (e.g., IL-10, TGF-β) and are involved in suppressing effective immune responses against tumors, thereby promoting tumor progression and metastasis [12].

In many cancers, TAMs predominantly exhibit an M2-like phenotype, which contributes to a pro-tumorigenic microenvironment. The plasticity of macrophages allows for a spectrum of activation states, and TAMs can exhibit a continuum between M1 and M2 phenotypes based on environmental cues [13,14].

Mechanisms of Cancer Immunoevasion

Tumor-associated macrophages (TAMs) are central players in helping tumors evade the immune system [6]. They contribute to cancer immunoevasion through several interrelated mechanisms that dampen the immune response and create a tumor-promoting environment. These include the production of immunosuppressive cytokines, recruitment of regulatory T cells (Tregs), impaired antigen presentation, expression of immune checkpoint molecules, and remodeling of the extracellular matrix [15].

1. Cytokine Production

TAMs secrete immunosuppressive cytokines, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which play a key role in suppressing the activation and function of effector immune cells [16]. IL-10 inhibits the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, both critical for mounting an effective anti-tumor immune response. TGF-β further contributes by inhibiting the proliferation and activation of T cells, including CD8+ T cells, which are essential for directly attacking and destroying tumor cells [17]. This creates an immunosuppressive environment that allows tumor cells to evade detection and elimination by the immune system, promoting tumor survival and progression.

2. Regulatory T Cell (Treg) Recruitment

TAMs promote the recruitment and expansion of regulatory T cells (Tregs) within the tumor microenvironment. Tregs are immune cells known for their ability to suppress immune responses and maintain immune tolerance [18]. By increasing Treg populations, TAMs enhance immunosuppression, which inhibits the activation and proliferation of cytotoxic T cells, further hindering the immune system's capacity to target and destroy cancer cells. This recruitment creates a feedback loop of immunosuppression, enhancing the tumor's ability to evade immune surveillance.

OPEN ACCESS
ONLINE ISSN: 2992-5797
PRINT ISSN: 2992-6122

3. Impaired Antigen Presentation

Antigen presentation is critical for initiating an effective immune response against tumors. While M1 macrophages are highly efficient at presenting antigens to T cells, TAMs often exhibit impaired antigen presentation capabilities [19]. They express lower levels of major histocompatibility complex (MHC) molecules, reducing their ability to activate CD8+ T cells [20]. This diminishes the immune system's ability to recognize and attack tumor cells, allowing the cancer to grow unchecked.

4. Expression of Immune Checkpoint Molecules

TAMs can also express immune checkpoint molecules such as programmed death-ligand 1 (PD-L1). When PD-L1 on TAMs binds to its receptor PD-1 on T cells, it sends an inhibitory signal that reduces T cell activation and proliferation [21]. This engagement of immune checkpoint pathways leads to a diminished anti-tumor immune response, further enabling tumors to evade immune surveillance. This mechanism also contributes to the resistance of tumors to immune checkpoint inhibitors, as TAMs maintain the immunosuppressive state.

5. Matrix Remodeling and Physical Barriers

TAMs contribute to the remodeling of the extracellular matrix (ECM), creating physical barriers that limit immune cell infiltration into the tumor. By producing enzymes like matrix metalloproteinases (MMPs), TAMs restructure the ECM, making it denser and more difficult for immune cells, particularly T cells and NK cells, to penetrate the tumor mass [22]. This spatial hindrance is a critical aspect of immune evasion, as it isolates tumor cells from immune attack and facilitates further tumor progression.

These multifaceted mechanisms underscore the pivotal role TAMs play in enabling cancer cells to evade immune detection, making them attractive targets for therapeutic intervention.

Therapy Resistance

TAMs are also implicated in the resistance of tumors to various therapeutic interventions:

1. Chemotherapy Resistance

TAMs can secrete growth factors and cytokines that promote cancer cell survival, enhance DNA repair mechanisms, and stimulate cancer stem cell-like properties, leading to the development of chemotherapy resistance [23]. For instance, the production of IL-6 by TAMs has been shown to activate the STAT3 pathway in tumor cells, promoting their survival in the presence of chemotherapeutic agents [24].

2. Resistance to Targeted Therapies

TAMs can modulate the tumor microenvironment to support cancer cell survival and proliferation, undermining the efficacy of targeted therapies. They may facilitate compensatory signaling pathways that allow tumor cells to evade the effects of targeted inhibitors [25].

3. Immune Checkpoint Inhibitor Resistance

The presence of TAMs in the tumor microenvironment can attenuate the efficacy of immune checkpoint inhibitors (ICIs) by maintaining an immunosuppressive environment. TAMs' expression of immune checkpoint molecules can inhibit T cell activation and diminish the effectiveness of therapies aimed at reactivating the immune system [26,27].

4. Promoting Angiogenesis and Tumor Growth

TAMs secrete pro-angiogenic factors such as VEGF, facilitating the development of new blood vessels to supply the growing tumor [28]. This angiogenic support not only aids in tumor growth but also can contribute to therapeutic resistance by enhancing nutrient and oxygen supply.

Therapeutic Strategies Targeting TAMs

Given their critical role in promoting tumor progression, immune evasion, and therapy resistance, targeting tumor-associated macrophages (TAMs) has become a promising approach to enhance cancer treatment outcomes. Several therapeutic strategies have been developed and are currently being explored:

1. Macrophage Depletion

One approach to target TAMs is through macrophage depletion, which aims to reduce the number of immunosuppressive macrophages in the tumor microenvironment. This can be achieved using colony-stimulating factor 1 receptor (CSF1R) inhibitors, which block the signaling pathways that are essential for the recruitment and survival of TAMs [29]. Preclinical models and early-phase clinical trials have shown that CSF1R inhibitors can reduce TAM populations and enhance anti-tumor immune responses [30]. Depleting TAMs may also reduce their contribution to angiogenesis and tumor growth, thereby improving patient outcomes. However, challenges such as potential compensatory mechanisms by other immune cells remain an area of focus for researchers.

2. Repolarization of TAMs

Another promising strategy involves reprogramming TAMs from a tumor-promoting M2-like phenotype to a tumor-suppressing M1-like phenotype. This can be achieved through the administration of cytokines such as IFN-γ, or small molecules like TLR agonists that drive pro-inflammatory responses [31]. Repolarized M1-like TAMs can enhance anti-tumor immunity by promoting T cell activation, producing inflammatory cytokines, and directly

attacking tumor cells. This therapeutic reprogramming may provide a more sustainable approach compared to depletion, as it harnesses the existing macrophage population for a pro-inflammatory, anti-tumor function.

3. Combination Therapies

Targeting TAMs in combination with other therapies, such as immune checkpoint inhibitors or traditional chemotherapy, is also being explored to enhance the overall effectiveness of cancer treatment [32]. For example, reducing the immunosuppressive influence of TAMs can enhance the efficacy of immune checkpoint inhibitors like PD-1 or CTLA-4 inhibitors, which aim to reactivate the immune system's ability to fight cancer [33]. Similarly, combining TAM depletion or reprogramming with chemotherapy can increase tumor sensitivity to cytotoxic agents, improving patient responses.

4. Nanoparticle-Based Delivery

Nanotechnology provides an innovative strategy for targeting TAMs by delivering therapeutic agents directly to these cells. Nanoparticles can be engineered to deliver drugs, cytokines, or genetic material specifically to TAMs, thus minimizing off-target effects and enhancing treatment efficacy [34]. For instance, nanoparticles can be used to deliver CSF1R inhibitors or molecules that reprogram TAMs, leading to a more precise modulation of their function within the tumor microenvironment [35]. This targeted approach reduces systemic toxicity and allows for higher concentrations of therapeutics at the tumor site, increasing their effectiveness while limiting side effects. These TAM-targeting strategies hold great potential for improving cancer therapies, overcoming resistance, and enhancing patient outcomes, particularly in cancers characterized by dense TAM infiltration.

CONCLUSION

Tumor-associated macrophages play a critical role in cancer immunoevasion and therapy resistance. By creating an immunosuppressive microenvironment and supporting tumor growth, TAMs significantly impact patient outcomes in various cancers. Understanding the mechanisms by which TAMs contribute to these processes is essential for developing innovative therapeutic strategies aimed at enhancing anti-tumor immunity and overcoming resistance to treatment. Continued research in this area holds promise for improving the efficacy of cancer therapies and ultimately benefiting patients facing this complex disease.

REFERENCES

1. Yang S, Liu Q, Liao Q. Tumor-associated macrophages in pancreatic ductal adenocarcinoma: origin, polarization, function, and reprogramming. Frontiers in cell and developmental biology. 2021 Jan 11;8:607209.
2. Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cellular immunology. 2017 Jun 1;316:1-0.
3. Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I. M1/M2 macrophages and their overlaps–myth or reality?. Clinical Science. 2023 Aug;137(15):1067-93.
4. Aleebrahim-Dehkordi E, Deravi N, Fallahi MS, Rezaei N. Mechanisms Underlying Tumor-Associated Macrophages (TAMs)-Facilitated Metastasis. InHandbook of Cancer and Immunology 2023 Mar 2 (pp. 1-54). Cham: Springer International Publishing.
5. Stakheyeva M, Riabov V, Mitrofanova I, Litviakov N, Choynzonov E, Cherdyntseva N, Kzhyshkowska J. Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Current pharmaceutical design. 2017 Sep 1;23(32):4807-26.
6. Ge Z, Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Frontiers in oncology. 2020 Nov 3;10:590941.
7. Qiu J, Cheng Z, Jiang Z, Gan L, Zhang Z, Xie Z. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. International Journal of Molecular Sciences. 2024 May 17;25(10):5490.
8. De Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer cell. 2023 Mar 13;41(3):374-403.
9. Ugel S, Canè S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annual Review of Pathology: Mechanisms of Disease. 2021 Jan 24;16(1):93-122.
10. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Afshari JT, Sahebkar A. Macrophage plasticity, polarization, and function in health and disease. Journal of cellular physiology. 2018 Sep;233(9):6425-40.
11. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Afshari JT, Sahebkar A. Macrophage plasticity, polarization, and function in health and disease. Journal of cellular physiology. 2018 Sep;233(9):6425-40.
12. Zhang Q, Sioud M. Tumor-associated macrophage subsets: shaping polarization and targeting. International journal of molecular sciences. 2023 Apr 19;24(8):7493.

13. Augustine TN, Nweke EE, Fru PN. Macrophage Polarization in the Tumor Microenvironment: Modulation and Mimicry. InHandbook of Cancer and Immunology 2022 Dec 13 (pp. 1-25). Cham: Springer International Publishing.
14. Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of macrophage plasticity in the tumor environment: manipulating activation state to improve outcomes. Frontiers in immunology. 2021 May 7;12:642285.
15. Huang R, Kang T, Chen S. The role of tumor-associated macrophages in tumor immune evasion. Journal of Cancer Research and Clinical Oncology. 2024 May 7;150(5):238.
16. Pernot S, Evrard S, Khatib AM. The giveand-take interaction between the tumor microenvironment and immune cells regulating tumor progression and repression. Front Immunol 13 (13): 850856.
17. Aftabi S, Barzegar Behrooz A, Cordani M, Rahiman N, Sadeghdoust M, Aligolighasemabadi F, Pistorius S, Alavizadeh SH, Taefehshokr N, Ghavami S. Therapeutic targeting of TGF-β in lung cancer. The FEBS Journal. 2024 Jul 31.
18. Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Frontiers in immunology. 2020 Dec 3;11:583084.
19. Shen X, Zhou S, Yang Y, Hong T, Xiang Z, Zhao J, Zhu C, Zeng L, Zhang L. TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress. Frontiers in Oncology. 2022 Nov 7;12:1034842.
20. Piatakova A, Polakova I, Smahelova J, Johari SD, Nunvar J, Smahel M. Distinct responsiveness of tumor-associated macrophages to immunotherapy of tumors with different mechanisms of major histocompatibility complex class I downregulation. Cancers. 2021 Jun 19;13(12):3057.
21. Pu Y, Ji Q. Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Frontiers in immunology. 2022 May 3;13:874589.
22. Rossi GR, Trindade ES, Souza-Fonseca-Guimaraes F. Tumor microenvironment-associated extracellular matrix components regulate NK cell function. Frontiers in Immunology. 2020 Jan 29;11:73.
23. Lafta HA, AbdulHussein AH, Al-Shalah SA, Alnassar YS, Mohammed NM, Akram SM, Qasim MT, Najafi M. Tumor-associated macrophages (TAMs) in cancer resistance; modulation by natural products. Current topics in medicinal chemistry. 2023 May 1;23(12):1104-22.
24. Dallavalasa S, Beeraka NM, Basavaraju CG, Tulimilli SV, Sadhu SP, Rajesh K, Aliev G, Madhunapantula SV. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis-current status. Current medicinal chemistry. 2021 Dec 1;28(39):8203-36.
25. Aizaz M, Khan A, Khan F, Khan M, Musad Saleh EA, Nisar M, Baran N. The cross-talk between macrophages and tumor cells as a target for cancer treatment. Frontiers in Oncology. 2023 Nov 14;13:1259034.
26. Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharmaceutica Sinica B. 2020 Nov 1;10(11):2156-70.
27. Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Molecular Cancer. 2023 Mar 21;22(1):58.
28. Larionova I, Kazakova E, Gerashchenko T, Kzhyshkowska J. New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis. Cancers. 2021 Jun 29;13(13):3253.
29. O'Brien SA, Orf J, Skrzypczynska KM, Tan H, Kim J, DeVoss J, Belmontes B, Egen JG. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunology, Immunotherapy. 2021 Aug;70:2401-10.
30. Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nature Reviews Drug Discovery. 2022 Nov;21(11):799-820.
31. Khan SU, Khan MU, Azhar Ud Din M, Khan IM, Khan MI, Bungau S, Hassan SS. Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy. Frontiers in Immunology. 2023 Apr 17;14:1166487.
32. Chyuan IT, Chu CL, Hsu PN. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers. 2021 Mar 10;13(6):1188.
33. Chamseddine AN, Assi T, Mir O, Chouaib S. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Pharmacology & therapeutics. 2022 Mar 1;231:107986.
34. Ding X, Sun X, Cai H, Wu L, Liu Y, Zhao Y, Zhou D, Yu G, Zhou X. Engineering macrophages via nanotechnology and genetic manipulation for cancer therapy. Frontiers in Oncology. 2022 Jan 6;11:786913.

35. He Y, de Araújo Júnior RF, Cruz LJ, Eich C. Functionalized nanoparticles targeting tumor-associated macrophages as cancer therapy. Pharmaceutics. 20
21 Oct 13;13(10):1670.

CITE AS: Mugisha Emmanuel K. (2024). The Role of Tumor-Associated Macrophages in Cancer Immunoevasion and Therapy Resistance. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES, 5(3):28-33 https://doi.org/10.59298/NIJBAS/2024/5.3.283311